Fever of Unknown Origin in Febrile Leukopenia

Infectious Disease Clinics of North America

Volumn 21, Issue 4, 2007, Pages 1055-1090

  Antoniadou, Anastasia ^a   Giamarellou, Helen ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; C REACTIVE PROTEIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DORIPENEM; IMIPENEM; ITRACONAZOLE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POSACONAZOLE; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CANDIDIASIS; CLINICAL EXAMINATION; CLINICAL FEATURE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE DURATION; FEBRILE NEUTROPENIA; FUNGAL DETECTION; FUNGUS IDENTIFICATION; HUMAN; INFECTION PREVENTION; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; PATIENT ASSESSMENT; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PYREXIA IDIOPATHICA; REVIEW; SCREENING TEST; THERAPY EFFECT; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BACTERIAL INFECTIONS; FEVER OF UNKNOWN ORIGIN; HUMANS; LEUKOPENIA; MYCOSES; NEOPLASMS;

EID: 36448984852     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.08.008     Document Type: Review

References (184)

1. Crawford J., Dale D.C., and Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100 2 (2004) 228-237
2. Bodey G.P., Buckley M., Sathe Y.S., et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 2 (1966) 328-340
3. Sickles E.A., Greene W.H., and Wiernick P.H. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135 5 (1975) 715-719
4. Pizzo P.A. Management of fever in patients with cancer and treatment induced neutropenia. N Engl J Med 328 18 (1993) 1323-1332
5. Bodey G.P. Unusual presentations of infection in neutropenic patients. Int J Antimicrob Agents 16 2 (2000) 93-95
6. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 6 (2002) 730-751
7. Immunocompromized Host Society. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis 161 3 (1990) 397-401
8. Link H., Bohme A., Cornely O.A., et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Study Group Interventional Therapy of Unexplained Fever. Ann Hematol 82 Suppl 2 (2003) S105-S117
9. Oude Nijhuis C.S., Daenen S.M., Vellenga E., et al. Fever and neutropenia in cancer patients: the diagnostic role of cytokines in risk assessment strategies. Crit Rev Oncol Hematol 44 2 (2002) 163-174
10. Rolston K.V. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments. Clin Infect Dis 39 Suppl 1 (2004) S44-S48
11. Dompeling E.C., Donnelly J.P., Raemaekers J.M., et al. Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy. Infection 26 6 (1998) 349-354
12. Rolston K.V. Prediction of neutropenia. Int J Antimicrob Agents 16 2 (2000) 113-115
13. National Cancer Institute. Common toxicity criteria, version 2.0. Available at: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf. Accessed April 30, 1999.
14. Dale D.C., Guerry IV D., Wewerka J.R., et al. Chronic neutropenia. Medicine (Baltimore) 58 2 (1979) 128-144
15. Rubin M., Hathom J.W., and Pizzo P.A. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 6 2 (1988) 167-184
16. Scott S. Identification of cancer patients at high risk of febrile neutropenia. Am J Health-Syst Pharm 59 Suppl 4 (2002) S16-S19
17. Silber J.H., Fridman M., DiPaola R.S., et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 16 7 (1998) 2392-2400
18. Chrischilles E., Link B., Scott S., et al. Factors associated with early termination of CHOP, and its association with overall survival among patients with intermediate-grade non-Hodgkin's lymphoma (NHL). [abstract 1539]. Proc Am Soc Clin Oncol 21 (2002) 385a
19. Giamarellou H., and Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clin North Am 15 2 (2001) 457-482
20. Viscoli C., Varnier O., and Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40 Suppl 4 (2005) S240-S245
21. Dale D.C., Crawford J., and Lyman G. Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review. [abstract 1638]. Proc Am Soc Clin Oncol 20 (2001) 410a
22. Gomez H., Hidalgo M., Casanova L., et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol 16 6 (1998) 2065-2069
23. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe-graft- versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102 8 (2003) 2768-2776
24. Neth O., Turner M.W., and Klein N.J. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 358 9282 (2001) 614-618
25. Pizzo P.A. Fever in immunocompromized patients. N Engl J Med 341 12 (1999) 893-900
26. Schimpff S.C. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 80 5c (1986) 13-20
27. Kreger B.E., Craven D.E., and McCabe W.R. Gram-negative bacteremia IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68 3 (1980) 344-355
28. Bodey G.P., Jadeja L., and Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 145 9 (1985) 1621-1629
29. Fergie J.E., Schema S.J., Lott L., et al. Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome. Clin Infect Dis 18 3 (1994) 390-394
30. Schimpff S., Satterlee W., Young V., et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284 19 (1971) 1061-1065
31. Hann I., Viscoli C., Paesmans M., et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group. (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 99 3 (1997) 580-588
32. Malik I.A., Khan W.A., Aziz Z., et al. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms. Clin Infect Dis 19 3 (1994) 522-527
33. Klaassen R.J., Goodman T.R., Pham B., et al. Low-risk prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 18 5 (2000) 1012-1019
34. Vidal L., Paul M., Ben-Dor I., et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Syst Rev 18 4 (2004) CD003992
35. Talcott J.A., Finberg R., Mayer R.J., et al. The medical course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med 148 12 (1988) 2561-2568
36. Talcott J.A., Siegel R.D., Finberg R., et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10 2 (1992) 316-322
37. Kern W.V., Cometta A., De Bock R., et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 341 5 (1999) 312-318
38. Freifeld A., Marchigiani D., Walsh T., et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341 5 (1999) 305-311
39. Klastersky J., Paesmans M., Rubenstein E.B., et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 16 (2000) 3038-3051
40. Klastersky J. Management of fever in neutropenic patients with different risk of complications. Clin Infect Dis 39 Suppl 1 (2004) S32-S37
41. Uys A., Rapoport B.L., and Anderson R. Febrile neutropenia: a prospective study to validate the multinational association of supportive care of cancer (MASCC) risk-index score. Support Care Cancer 12 8 (2004) 555-560
42. Klastersky J., and Paesmans M. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer 15 (2007) 477-482
43. Meunier F. Infections in patients with acute leukemia and lymphoma. In: Mandel G.L., Douglas J.V., and Bennett J.E. (Eds). Principles and practice of infections diseases. 4th edition (1995), Churchill Livingstone Inc, Philadelphia 2675-2686
44. Mermel L.A., Farr B.M., Sherertz R.J., et al. Guidelines for the management of intravascular catheter-related infection. Clin Infect Dis 32 9 (2001) 1249-1272
45. Valdiviesco M., Gil-extremera B., Zornoza J., et al. Gram-negative bacillary pneumonia in the compromised host. Medicine (Baltimore) 56 3 (1977) 241-254
46. Heussel C.P., Kauczor H.U., Heussel G.E., et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem cell transplant recipients: use of high resolution computed tomography. J Clin Oncol 17 3 (1999) 796-805
47. Caillot D., Couaillier J.F., Bernard A., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 19 1 (2001) 253-259
48. Hauhhaard A., Ellis M., and Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 43 3 (2002) 292-298
49. Gorschluter M., Mey U., Strehl J., et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol 75 1 (2005) 1-13
50. Kontoyiannis D.P., Luna M.A., Samuels B.I., et al. Hepatosplenic candidiasis. Infect Dis Clin North Am 14 3 (2000) 721-739
51. Sudhoff T., Giagonnidis A., and Karthaus M. Evaluation of neutropenic fever: value of serum and plasma parameters in clinical practice. Chemotherapy 46 2 (2000) 77-85
52. Muller B., Becker K.L., Schachinger H., et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28 4 (2000) 977-983
53. Tugrul S., Esen F., Celebi S., et al. Reliability of procalcitonin as a severity marker in critically ill patients with inflammatory response. Anaesth Intensive Care 30 6 (2002) 747-754
54. Jimeno A., Garia-Velasco A., del Val O., et al. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100 11 (2004) 2462-2469
55. Giamarellos-Bourboulis E.J., Grecka P., Poulakou G., et al. Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 32 12 (2001) 1718-1725
56. Ruokonen E., Nousiainen T., Pulkki K., et al. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis 18 4 (1999) 283-285
57. Engel A., Steinbach G., Kern P., et al. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 31 2 (1999) 185-189
58. Fleischhack G., Kambeck I., Cipic D., et al. Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. Br J Haematol 111 4 (2000) 1093-1102
59. Persson L., Engervall P., Magnuson A., et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 36 5 (2004) 365-371
60. Ortega M., Rovira M., Filella X., et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation. Br J Haematol 126 3 (2004) 372-376
61. Dornbusch H.J., Strenger V., Kerbl R., et al. Procalcitonin-a marker of invasive fungal infection?. Support Care Cancer 13 5 (2005) 343-346
62. Schüttrumpf S., Binder L., Hagemann T., et al. Procalcitonin: a useful discriminator between febrile conditions of different origin in hemato-oncological patients?. Ann Hematol 82 2 (2003) 98-103
63. Persson L., Soderquist B., and Engervall P. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 74 4 (2005) 297-303
64. Arber C., Passweg J.R., Fluckiger U., et al. C-reactive protein and fever in neutropenic patients. Scand J Infect Dis 32 5 (2000) 515-520
65. Yonemori K., Kanda Y., Yamamoto R., et al. Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients. Leuk Lymphoma 41 5-6 (2001) 607-614
66. Manian F.A. A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. Clin Infect Dis 21 1 (1995) 114-121
67. Ortega M., Rovira M., Almela M., et al. Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant 33 7 (2004) 741-744
68. Maertens J., Van Eldere J., Verhaegen J., et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 186 9 (2002) 1297-1306
69. Viscoli C., Machetti M., and Gazzola P. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 40 4 (2002) 1496-1499
70. Maertens J., Theunissen K., Verbeken E., et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 126 6 (2004) 852-860
71. Marr K.A., Balajee S.A., McLaughlin L., et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190 3 (2004) 641-649
72. Mennink-Kersten M.A., Donnelly J.P., and Verveij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 4 6 (2004) 349-357
73. Wheat L.J. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis 5 4 (2003) 158-166
74. Mattei D., Rapezzi D., Mordini N., et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 42 11 (2004) 5362-5363
75. Husain S., Kwak E.J., Obman A., et al. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 4 5 (2004 May) 796-802
76. Blijlevens N.M., Donnelly J.P., Meis J.F., et al. Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. Transpl Infect Dis 4 2 (2002) 64-65
77. Mennink-Kersten M.A., Klont R.R., Warris A., et al. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 363 9405 (2004) 325-327
78. Pinel C., Fricker-Hidalgo H., Lebeau B., et al. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 41 5 (2003) 2184-2186
79. Swanink C.M., Meis J.F., Rijs A.J., et al. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 35 1 (1997) 257-260
80. Klont R.R., Mennink-Kersten M.A., et al. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 39 10 (2004) 1467-1474
81. Pfeiffer C.D., Fine J.P., and Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42 10 (2006) 1417-1427
82. Maertens J., Theunissen K., Verhoef G., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 9 (2005) 1242-1250
83. Odabasi Z., Mattiuzzi G., Estey E., et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 39 2 (2004) 199-205
84. Pickering J.W., Sant H.W., Bowles C.A., et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 43 12 (2005) 5957-5962
85. Pezos C., Pontoon J., and Del Palacio A. Contribution of (1->3)-beta-D-glucan chromomeric assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 43 1 (2005) 299-305
86. Musher B., Fredrick's D., Leistering W., et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 42 12 (2004) 5517-5522
87. Kapaau M., Kanda Y., Nanny Y., et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42 6 (2004) 2733-2741
88. Holliday C., Hole R., Sorrell T., et al. Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia. Br J Haematol 132 (2005) 478-486
89. Florent M., Katsahian S., Vekhoff A., et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 193 5 (2006) 741-747
90. White P.L., Linton C.J., Perry M.D., et al. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin Infect Dis 42 4 (2006) 479-486
91. Buchheidt D., Baust C., Skladny H., et al. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 116 4 (2002) 803-811
92. Sendid B., Caillot D., Baccouch-Humbert B., et al. Contribution of the Platelia Candida-specific antibody and antigen tests to early diagnosis of systemic Candida tropicalis infection in neutropenic adults. J Clin Microbiol 41 10 (2003) 4551-4558
93. Kondori N., Edebo L., and Mattsby-Baltzer I. Circulating (1-3) glucan and immunoglobulin G subclass antibodies to Candida albicans cell wall antigens in patients with systemic candidiasis. Clin Diagn Lab Immunol 11 2 (2004) 344-350
94. Pappas P.G., Rex J.H., Sobel J.D., et al. Guidelines for the treatment of candidiasis. Clin Infect Dis 38 2 (2004) 161-189
95. Antoniadou A., Torres H.A., Lewis R.E., et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 82 5 (2003) 309-321
96. Hospenthal D.R., Murray C.K., and Rinaldi M.G. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis 48 3 (2004) 153-160
97. Pfaller M.A., and Diekema D.J. International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 10 Suppl 1 (2004) 11-23
98. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39 Suppl 1 (2004) S25-S31
99. Winston D.J., Lazarus H.M., Beveridge R.A., et al. Randomized, doubleblind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 32 3 (2001) 381-390
100. Feld R., DePauw B., Berman S., et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol 18 21 (2000) 3690-3698
101. Del Favero A., Menichetti F., Martino P., et al. A multicenter, doubleblind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 33 8 (2001) 1295-1301
102. Cordonnier C., Buzyn A., Leverger G., et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 36 2 (2003) 149-158
103. Rolston K.V. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 40 Suppl 4 (2005) S246-S252
104. Yadegarynia D., Tarrand J., Raad I., et al. Current spectrum of bacterial infections in patients with cancer. Clin Infect Dis 37 8 (2003) 1144-1145
105. Rolston K.V., and Tarrand J.J. Pseudomonas aeruginosa: still a frequent pathogen in patients with cancer: 11-year experience at a comprehensive cancer center. Clin Infect Dis 29 2 (1999) 463-464
106. Raje N.S., Rao S.R., Iyer R.S., et al. Infection analysis in acute lymphoblastic leukaemia: a report of 499 consecutive episodes in India. Pediatr Hematol Oncol 11 3 (1994) 271-280
107. Wisplinghoff H., Seifert H., Wenzel R.P., et al. Current trends in the epidemiology of nosocomial blood stream infections in patients with haematological malignancies and sold neoplasms in hospitals in the United States. Clin Infect Dis 36 9 (2003) 1103-1110
108. Tunkel A.R., and Sepkowitz K.A. Infections caused by viridans streptococci in patients with neutropenia. Clin Infect Dis 34 11 (2002) 1524-1529
109. Gales A.C., Jones R.N., Turnidge J., et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 Suppl 2 (2001) S146-S155
110. Bell J.M., Turnidge J.D., Gales A.C., et al. Prevalence of extended-spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 42 3 (2002) 193-198
111. Fainstein V., Elting L.S., and Bodey G.P. Bacteremia caused by non-sporulating anaerobes in cancer patients: a 12 year experience. Medicine (Baltimore) 68 3 (1989) 151-162
112. Paul M., Soares-weiser K., and Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination for fever with neutropenia: systematic review and meta-analysis. BMJ 327 7399 (2003) 1111-1121
113. Aiken S.K., and Wetzstein G.A. Once-daily aminoglycosides in patients with neutropenic fever. Oncol Pharm 9 5 (2002) 426-431
114. Pizzo P.A., Hathorn J.W., Himenez J., et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315 9 (1986) 552-558
115. Yamamura D., Gucalp R., Carlisle P., et al. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother 41 8 (1997) 1704-1708
116. Cometta A., Calandra T., Gaya H., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40 5 (1996) 1108-1115
117. Paul M., Yahav D., Fraser A., et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 57 2 (2006) 176-189
118. Bodey G.P., Middleman E., Umsawadi T., et al. Infections in cancer patients: results with gentamycin sulfate therapy. Cancer 29 6 (1972) 1697-1701
119. Giamarellou H., Bassaris H.P., Petrikkos G., et al. Monotherapy with intravenous followed by oral high dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. Antimicrob Agents Chemother 44 12 (2000) 3264-3271
120. Chamilos G., Bamias A., Efstathiou E., et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer 103 12 (2005) 2629-2635
121. Talcott J.A. Out-patient management of febrile neutropenia. Int J Antimicrob Agents 16 2 (2000) 169-171
122. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada-Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163 5 (1991) 951-958
123. Raad II, Escalante C., Hachem R.Y., et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 98 5 (2003) 1039-1047
124. Rubin M., Hathorn J.W., Marshall D., et al. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108 1 (1988) 30-35
125. Paul M., Borok S., Fraser A., et al. Empirical antibiotics against gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55 4 (2005) 436-444
126. Cometta A., Kern W.V., De Bock R., et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37 3 (2003) 382-389
127. Erjavec Z., de Vries-Hospers H.G., Laseur M., et al. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy. J Antimicrob Chemother 45 6 (2000) 843-849
128. Menichetti F. The role of teicoplanin in the treatment of febrile neutropenia. J Chemother 12 Suppl 5 (2000) S34-S39
129. Jaksic B., Martinelli G., Perez-Oteyza J., et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 42 5 (2006) 597-607
130. Poutsiaka D.D., Skiffington S., Miller K.B., et al. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 54 6 (2007) 567-571
131. Badbugs, no drugs. Available at: www.idsociety.org. Accessed July 2004.
132. Talbot G.H., Bradley J., Edwards J.E., et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 42 5 (2006) 657-668
133. Giamarellou H. Multidrug resistance in gram-negative bacteria that produce extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 11 Suppl 4 (2005) 1-16
134. Extended spectrum β-lactamases tables. Available at: www.lahey.org/studies/webt.htm. Accessed October 4, 2007.
135. Turner P.J. Extended-spectrum β-lactamases. Clin Infect Dis 41 Suppl 4 (2005) 273-275
136. Paterson D.L., Ko W.C., Gottberg A.V., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended spectrum β-lactamases. Clin Infect Dis 39 1 (2004) 31-37
137. Walsh T.R., Toleman M.A., Poirel L., et al. Metallo-β-lactamases: the quiet before the storm?. Clin Microbiol Rev 18 2 (2005) 306-325
138. Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Available at: www.cdc.gov/ncidod/dhqp/pdf/nnis/2003NNISReport_AJIC.PDF.
139. Souli M., Kontopidou F.V., Koratzanis E., et al. In vitro activity of tigecycline against multiple-drug resistant, influencing pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 50 9 (2006) 3166-3169
140. Ellis-Grosse E.J., Babinchak T., Dartois N., et al., for the Tigecycline 300 and 305 cSSSI Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin/aztreonam. Clin Infect Dis 41 Suppl 5 (2005) 341-353
141. Bobinchak T., Ellis-Grosse E., Dartois N., et al., for the Tigecycline 301 and 306 Study Groups. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41 Suppl 5 (2005) 354-366
142. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multi-drug resistant gram-negative bacterial infections. Clin Infect Dis 40 9 (2005) 1333-1341
143. Gales A.C., Jones R.N., and Sader H.S. Global assessment of the antimicrobial activity of polymyxin against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance program(2001-2004). Clin Microbiol Infect 12 4 (2006) 315-321
144. Giamarellos-Bourboulis E.J., Sambatakou H., Galani I., et al. In vitro interaction of colistin and rifampin on multidrug resistant Pseudomonas aeruginosa. J Chemother 15 3 (2003) 235-238
145. Falagas M.E., Fragoulis K.N., Kasiakou S.K., et al. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 26 6 (2005) 504-507
146. Hachem R.Y., Chemaly R.F., Ahmar C.A., et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 51 6 (2007) 1905-1911
147. Ostronoff M., Ostronoff F., Sucupira A., et al. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis 10 (2006) 339-340
148. Jones R.N., Sader H.S., and Fritsche T. Comparative activity of doripenem and three other carbapenems tested against gram-negative bacilli with various β-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 52 1 (2005) 71-74
149. Horiuchi M., Kimura M., Tokumura M., et al. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 222 1-2 (2006) 114-124
150. Wingard J.R. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 39 Suppl 1 (2004) S38-S43
151. Sipsas N.V., Bodey G.P., Kontoyiannis D.P., et al. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century. Cancer 103 6 (2005) 1103-1113
152. Pizzo P.A., Robichaud K.J., Gill F.A., et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72 1 (1982) 101-111
153. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86 6 Pt 1 (1989) 668-672
154. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 340 10 (1999) 764-771
155. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 14 (2004) 1391-1402
156. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 346 4 (2002) 225-234
157. Vigourouz S., Morin O., Moreau P., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 40 4 (2005) e35-e37
158. Chamilos G., Marom E.M., Lewis R.E., et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41 1 (2005) 60-66
159. Elting L.S., Rubenstein E.B., Rolston K., et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 18 21 (2000) 3699-3706
160. Corey L., and Boeckh M. Persistent fever in patients with neutropenia. N Engl J Med 346 4 (2002) 222-224
161. Kern W.V. Modifications of therapy. Int J Antimicrob Agents 16 2 (2000) 139-141
162. Leather H.L., and Wingard J.R. Infections following hematopoietic stem cell transplantation. Infect Dis Clin North Am 15 2 (2001) 483-520
163. Clark O.A., Lyman G., Castro A.A., et al. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 3 (2003) CD003039
164. Cheng A.C., Stephens D.P., and Curie B.J. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 3 (2004) CD004400
165. Smith T.J., Khatcharessian J., Lyman G.H., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence based clinical practice guideline. J Clin Oncol 24 19 (2006) 3187-3205
166. Gafter-Gvilli A., Fraser A., Paul M., et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142 12 Pt 1 (2005) 979-995
167. van de Wetering M.D., de Witte M.A., Kremer L.C.M., et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 41 10 (2005) 1372-1382
168. Engels E.A., Lau J., Barza M., et al. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 16 3 (1998) 1179-1187
169. Cruciani M., Rampazzor R., Malena M., et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23 4 (1996) 795-805
170. Cullen M., Steven N., Billingham L., et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353 (2005) 988-998
171. Bucaneve G., Micozzi A., Menichetti F., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 (2005) 977-987
172. Gotzsche P.C., and Johansen H.K. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2 (2002) CD000026
173. Goodman J.L., Winston D.J., Greenfield R.A., et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326 13 (1992) 845-851
174. Kanda Y., Yamamoto R., Chizuka A., et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: a meta-analysis of 16 randomized, controlled trials. Cancer 89 7 (2000) 1611-1625
175. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
176. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
177. Ascioglou S., de Pauw B.E., and Meis J. Prophylaxis and treatment of fungal infections associated with haematological malignancies. Int J Antimicrob Agents 15 3 (2000) 159-168
178. Dykewicz C.A. Hospital infection control in haematopoietic stem cell transplant recipients. Emerg Infect Dis 7 2 (2001) 263-267
179. Owczuk R., Wujtewicz M.A., Sawicka W., et al. Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit. Support Care Cancer 13 5 (2005) 332-338
180. Blot F., Guiguet M., Nitenberg G., et al. Prognostic factors for neutropenic patients in an intensive care unit: respective roles of underlying malignancies and acute organ failures. Eur J Cancer 33 7 (1997) 1031-1037
181. Staudinger T., Stoiser B., and Mullner M. Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 28 5 (2000) 1322-1328
182. Price K.J., Thall P.F., Susannah K.K., et al. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med 158 3 (1998) 876-884
183. Regazzoni C.J., Irrazabal C., Luna C.M., et al. Cancer patients with septic shock: mortality predictors and neutropenia. Support Care Cancer 12 12 (2004) 833-839
184. Gruson D., Hilbert G., and Vargas F. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients. Crit Care Med 28 9 (2000) 3155-3160